Navigation Links
LSUHSC research finds treating stress prevented new MS brain lesions
Date:7/16/2012

New Orleans, LA Research conducted by Jesus Lovera, MD, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has shown that stress management treatment significantly reduced the formation of new brain lesions in people with multiple sclerosis (MS) over the course of treatment. These lesions are markers of disease activity used to objectively measure disease status. The work is published ahead of print and is now available online in Neurology.

"Our research found that 77% of the patients undergoing stress management therapy remained free of lesions while they were in treatment compared to 55% of those in the control group," notes Dr. Jesus Lovera, an LSU Health Sciences Center New Orleans board certified neurologist whose research and practice focus on multiple sclerosis.

The research team studied 121 patients with relapsing forms of MS, most of whom are women. They were randomly assigned to receive stress management therapy for MS or were wait-listed while continuing to receive their usual treatment for MS. The therapy group received 16 individual treatment sessions over 24 weeks, and were then followed for an additional 24 weeks.

The sessions included teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, and insomnia treatment.

MRIs were performed at the start of the study as well as at weeks 8, 16, 24, 32, 40 and 48. They revealed that while lesions were prevented or reduced during stress therapy, the benefit did not continue beyond treatment. Possible explanations include the need for longer, or possibly indefinite stress management therapy, participants
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. Research reveals first evidence of hunting by prehistoric Ohioans
4. Diabetes Research Institute develops oxygen-generating biomaterial
5. APS issues new policy requiring identification of sex or gender in reporting scientific research
6. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
7. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
8. U of Alberta researcher steps closer to understand autoimmune diseases
9. Research on flavanols and procyanidins provides new insights into how these phytonutrients may positively impact human health
10. A project to research biological and chemical aspects of microalgae to fuel approach
11. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Covalys Biosciences AG today announced a collaboration to ... generate SNAP-tag fusion proteins based on Gene Bridges' ... does not require restriction enzymes and allows the ... (bacterial artificial chromosomes) with single-nucleotide precision. SNAP-tag is ...
... Like humans, other animals are faced with everyday obstacles ... and motor skills to deal with them. Navigating these ... other vertebrates, but in new work, researchers have employed ... structure of goal-oriented motor programs in the fruit fly ...
... help stem the global HIV epidemic is to give ... drug tenofovir) before they have high risk sex in ... an approach called "pre-exposure prophylaxis" (PREP). But activist groups, ... least two important clinical trials of tenofovir as PREP ...
Cached Biology News:Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits 2Gap-climbing fruit flies reveal components of goal-driven behaviors 2Why were the HIV prevention trials in commercial sex workers abandoned? 2
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Toronto Stock Exchange Symbol: LRILAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ ... "Company") (TSX: LRI), a Canadian-based global non-clinical contract research ... Spalding as Chairman of its Board of Directors in ... wish to step down of the Board to focus ...
... and PARIS, February 9 Debiopharm,Group (Debiopharm), ... serious medical conditions and particularly oncology, and,Pharmaleads ... early development,company, today announced the signature of ... and commercialisation of a small molecule,called Debio ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading ... biopharmaceutical products primarily,in China, today announced that it ... effective February 1, 2009. Since joining 3SBio in ... financial advisor for the company, providing advice,on the ...
Cached Biology Technology:LAB Research announces changes to its Board of Directors 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 33SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2
... The H2OBIT is a fully licensed, high ... simultaneous processing of up to 24 microplates. This ... 384-well plates. ,A robotic arm rapidly transfers ... resulting in temperature ramping times that are considerably ...
... Rabbit polyclonal to Dideoxycytidine Dideoxycytidine is ... be effective in inhibiting retroviral activity. ... BSA. Specificity: The specificity of ... ratio of the moles of ddC to moles ...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... HM-4000 Multidizer is designed with a ... orbital, rotating - all in one unit. ... Two independently operating compartments allow for hybridization ... or motion , The upper chamber ...
Biology Products: